CAPTRUST Financial Advisors
AVIR icon

CAPTRUST Financial Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

CAPTRUST Financial Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-502
Closed -$4K – 2227
2022
Q2 		$4K Sell
502
-383
-43% -$2.62K ﹤0.01% 4160
2022
Q1 		$6K Buy
885
+62
+8% +$421 ﹤0.01% 4049
2021
Q4 		$7K Buy
+823
New +$12.8K ﹤0.01% 3892
2021
Q3 		– Sell
-26
Closed -$1K – 4639
2021
Q2 		$1K Buy
26
+22
+550% +$661 ﹤0.01% 4305
2021
Q1 		$0 Buy
+4
New +$270 ﹤0.01% 4373

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

CAPTRUST Financial Advisors's AVIR Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Atea Pharmaceuticals (AVIR) in Q3 2022, closing a stake of 502 shares — an estimated $4K sold.

CAPTRUST Financial Advisors first reported a position in AVIR in Q1 2021 and held it in 5 quarters. The position peaked at $7K in Q4 2021. 126 funds tracked by Wall St. Rank hold AVIR as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Atea Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 502 Atea Pharmaceuticals shares in Q3 2022, an estimated $4K.
  • CAPTRUST Financial Advisors first reported a position in Atea Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • CAPTRUST Financial Advisors's Atea Pharmaceuticals position peaked at $7K in Q4 2021.
  • 126 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.